We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Essential Fatty Acids for Major Depression

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00256412
First Posted: November 21, 2005
Last Update Posted: June 5, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University of Iowa
  Purpose

This is a research study to determine whether omega-3 fatty acid supplementation, when taken with the antidepressant medication escitalopram (Lexapro), helps to improve depressive symptoms in individuals who have major depressive disorder (MDD).

Omega-3 fatty acids are found in foods including walnuts, some fruits and vegetables, and coldwater fish such as herring, mackerel, sturgeon, and anchovies.


Condition Intervention
Major Depression Drug: Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Essential Fatty Acids in Management of MDD - A Pilot Study

Further study details as provided by University of Iowa:

Primary Outcome Measures:
  • Montgomery-Asberg Depression Rating Scale (MADRS) scores [ Time Frame: 4 - 10 weeks ]

Enrollment: 24
Study Start Date: October 2005
Study Completion Date: October 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1 Drug: Placebo
4 capsules of placebo each day
Active Comparator: 2
Low Dose
Drug: Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day
Placebo and Omega 3 capsules. All participants receive 4 capsules with either 0, 2, or 4 capsules containing omega 3.
Active Comparator: 3
High Dose
Drug: Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day
Placebo and Omega 3 capsules. All participants receive 4 capsules with either 0, 2, or 4 capsules containing omega 3.

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. DSM-IV criteria for nonpsychotic MDD
  2. Not currently on antidepressants OR not responding to a stable dose of antidepressants

Exclusion Criteria:

  1. DSM-IV for substance abuse in past month or dependence past year.
  2. Allergy to fish
  3. Bleeding disorder or taking warfarin
  4. Omega-3 supplements for more than three consecutive days in the preceding month
  5. Pregnant
  6. Taking medications (i.e. glucocorticoids) known to produce affective symptoms
  7. History of non-response to escitalopram
  8. DSM-IV for an eating disorder in the preceding year.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00256412


Locations
United States, Iowa
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States, 52242
Sponsors and Collaborators
University of Iowa
Investigators
Principal Investigator: William H Coryell, M.D. University of Iowa
Study Director: Jess G Fiedorowicz, M.D. University of Iowa
  More Information

Responsible Party: William Coryell, University of Iowa
ClinicalTrials.gov Identifier: NCT00256412     History of Changes
Other Study ID Numbers: IRB-01 200408033
First Submitted: November 16, 2005
First Posted: November 21, 2005
Last Update Posted: June 5, 2008
Last Verified: June 2008

Additional relevant MeSH terms:
Depression
Depressive Disorder
Depressive Disorder, Major
Behavioral Symptoms
Mood Disorders
Mental Disorders